Lv26
160 积分 2023-07-29 加入
Design, Synthesis, and Biological Evaluation of Selective CDK4/9 Inhibitors
5小时前
已完结
The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug
2天前
已完结
Design, Synthesis, and Biological Evaluation of Novel Arylomycins against Multidrug-Resistant Gram-Negative Bacteria
3天前
已完结
The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug
3天前
已完结
Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors – a review of patent literature from 2019–30 June 2023
5天前
已完结
A patent review of small molecule CDK4/6 inhibitors in the treatment of cancer: 2020–present
5天前
已完结
Analyzing the scaffold diversity of cyclin‐dependent kinase inhibitors and revisiting the clinical and preclinical pipeline
5天前
已完结
Discovery of FHD-286, a First-in-Class, Orally Bioavailable, Allosteric Dual Inhibitor of the Brahma Homologue (BRM) and Brahma-Related Gene 1 (BRG1) ATPase Activity for the Treatment of SWItch/Sucrose Non-Fermentable (SWI/SNF) Dependent Cancers
9天前
已完结
A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
9天前
已完结
A patent review of small molecule CDK4/6 inhibitors in the treatment of cancer: 2020–present
13天前
已完结
皖公网安备34019202002308
